Literature DB >> 17468832

Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.

Carl P Herbort1, Manabu Mochizuki.   

Abstract

PURPOSE: To delineate the historical steps associated with the genesis of the name and the definition of Vogt-Koyanagi-Harada (VKH) disease.
METHODS: A bibliographical review of the major publications that were relevant to the original development of the name of the clinical entity known today as Vogt-Koyanagi-Harada disease, in the historical context of the early 20th century.
RESULTS: Three distinct time periods can be considered to be important in terms of providing a historical perspective on VKH disease. Given that the cutaneous manifestations of VKH disease are so characteristic, these could not have been missed even before the actual clinical entity of VKH was recognized in the early 20th century. Indeed, several authors, including the Arabic doctor Mohammad-al-Ghâfiqî in the 12th century as well as Jacobi, Nettelship and Tay in the 19th century, described poliosis, neuralgias and hearing disorders. Many of these cases were probably due to sympathetic ophthalmia, but some were clearly VKH cases. The second phase is characterized by the surge of articles that appeared early in the 20th century that defined the disease more precisely. A number of these authors subsequently became associated with the disease name, the first being Alfred Vogt from Switzerland, followed by Japanese researchers. Yoshizo Koyanagi was in fact not the first Japanese author to describe the disease; this honor goes to the first Japanese Professor of Ophthalmology at the University of Tokyo, Dr. Jujiro Komoto, who published in a German language journal, Klinische Monatsblätter für Augenheilkunde in 1911. Yoshizo Koyanagi published his first report in the Nippon Ganka Gakkai Zasshi 3 years later, in 1914, but it was a much later article, one published in 1929, that definitively associated his name with the disease. In this review article, Koyanagi reported 16 cases, of which six were his own cases, that beautifully illustrate the natural course of the disease. In this same time period, Einosuke Harada, in an article published in Nippon Ganka Gakkai Zasshi in 1926 that was based on several case studies, comprehensively described a syndrome that included (1) a prodromal phase of malaise and meningeal irritation; (2) bilateral uveitis of diverse intensity; (3) bilateral retinal detachments spontaneously resolving; (4) integumentary changes; (5) lymphocytosis of the spinal fluid; (6) dysacousia. It is now accepted that Vogt-Koyanagi disease and the syndrome described by Harada are one entity with a diverse clinical spectrum bearing the universally accepted name of Vogt-Koyanagi-Harada disease. The third phase and most recent phase is characterized by the rapid progress made in terms of knowledge of the physiopathology of the disease, primarily due to the development of immunological methods. The evidence accumulated to date clearly points towards an autoimmune Th1 disease directed against proteins associated with choroidal melanin. Other analytical techniques, such as indocyanine green angiography, have enabled researchers to monitor more closely the primary lesional process at the level of the choroid, and standardized diagnostic criteria have been generated in the recent past.
CONCLUSION: Those who earn scientific merit in clinical medicine are the ones who are able to visualize an overview based on the synthesis of 'new' medical facts that have been made available, usually reported singly by several, unassociated authors concomitantly. This is certainly the case for Yoshizo Koyanagi and Einosuke Harada. Conversely, Alfred Vogt was primarily lucky in that he encountered and subsequently precisely described the first case in the literature.

Entities:  

Mesh:

Year:  2007        PMID: 17468832     DOI: 10.1007/s10792-007-9083-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.029


  17 in total

1.  [Vogt-Koyanagi-Harada syndrome--historical changes in the eponym].

Authors:  Norio Ooba
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2006-02

2.  Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.

Authors:  Sunao Sugita; Hiroshi Takase; Chikako Taguchi; Yasuhisa Imai; Koju Kamoi; Tatsushi Kawaguchi; Yoshiharu Sugamoto; Yuri Futagami; Kyogo Itoh; Manabu Mochizuki
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-06       Impact factor: 4.799

3.  The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.

Authors:  N Bouchenaki; C P Herbort
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

4.  Vogt-Koyanagi-Harada syndrome after cutaneous injury.

Authors:  S R Rathinam; P Namperumalsamy; R A Nozik; E T Cunningham
Journal:  Ophthalmology       Date:  1999-03       Impact factor: 12.079

5.  Schematic interpretation of indocyanine green angiography in posterior uveitis using a standard angiographic protocol.

Authors:  C P Herbort; P LeHoang; Y Guex-Crosier
Journal:  Ophthalmology       Date:  1998-03       Impact factor: 12.079

6.  Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.

Authors:  S Sugita; K Sagawa; M Mochizuki; S Shichijo; K Itoh
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

7.  Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.

Authors:  K Yamaki; K Gocho; K Hayakawa; I Kondo; S Sakuragi
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

8.  Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.

Authors:  R W Read; G N Holland; N A Rao; K F Tabbara; S Ohno; L Arellanes-Garcia; P Pivetti-Pezzi; H H Tessler; M Usui
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

9.  Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease.

Authors:  K Norose; A Yano; F Aosai; K Segawa
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-07       Impact factor: 4.799

10.  HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410.

Authors:  Y Shindo; H Inoko; T Yamamoto; S Ohno
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

View more
  9 in total

Review 1.  Contributions to Progress in Ophthalmology from Switzerland: From the 16th to the 21st Century.

Authors:  Ronald D Gerste
Journal:  Ophthalmologica       Date:  2020-08-24       Impact factor: 3.250

2.  Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease.

Authors:  Narsing A Rao; Amod Gupta; Laurie Dustin; Soon Phaik Chee; Annabelle A Okada; Moncef Khairallah; Bahram Bodaghi; Phuc Lehoang; Massimo Accorinti; Manabu Mochizuki; Tisha Prabriputaloong; Russell W Read
Journal:  Ophthalmology       Date:  2009-12-24       Impact factor: 12.079

3.  Eponyms in dermatology literature linked to Japan.

Authors:  Ahmad Al Aboud; Khalid Al Aboud
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-01-12

Review 4.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24

5.  Unilateral Presentation of Vogt-Koyanagi-Harada Syndrome.

Authors:  Seyedeh Maryam Hosseini; Maryam Dourandish; Marjan Mazouchi
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02

Review 6.  Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review.

Authors:  Cristhian A Urzua; Carl P Herbort; Masaru Takeuchi; Ariel Schlaen; Luz E Concha-Del-Rio; Yoshihiko Usui; Loreto Cuitino; Ioannis Papasavvas
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-05-12

Review 7.  Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Ahmed Abu-El-Asrar; Amod Gupta; Masaru Takeuchi; Christine Fardeau; Alireza Hedayatfar; Cristhian Urzua; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2021-06-18       Impact factor: 3.775

Review 8.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

9.  [Vitiligo revealing Vogt -Koyanagi-Harada disease].

Authors:  Mohamed El Amraoui; Youssef Zemmez; Ahmed Bouhamidi; Rachid Frikh; Naoufal Hjira; Mohammed Boui
Journal:  Pan Afr Med J       Date:  2017-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.